Collegium Pharmaceutical (FRA:354) Probability of Financial Distress (%): 0.05% (As of Jun. 24, 2026)


FRA:354 Collegium Pharmaceutical Inc FRA:354
76 GF Score
Price €28.80
GF Value €35.50
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Collegium Pharmaceutical Probability of Financial Distress (%)?

Collegium Pharmaceutical FRA:354 76 Probability of Financial Distress (%) is 0.05% as of Jun. 24, 2026. GuruFocus rates FRA:354 with a GF Score™ of 76/100 and a GF Value™ of €35.50 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Probability of Financial Distress (%) measures the probability that a company will go bankrupt in the upcoming year given its current financial position. A higher ratio indicates a larger probability of bankruptcy for the company, while a lower ratio indicates a healthier fundamental. As of today, Collegium Pharmaceutical's Probability of Financial Distress (%) is 0.05%.

Like the Altman Z-Score, the PFD measures a company's bankruptcy risk. However, the main drawback of the Z-score is it does not apply to banks and insurance companies. According to Investopedia, the concept of "working capital" does not apply to banks and insurance companies, as financial institutions do not have typical current assets or current liabilities like inventories or accounts payable.


Collegium Pharmaceutical  (FRA:354) Probability of Financial Distress (%) Explanation

Like the Altman Z-Score, the PFD measures a company's bankruptcy risk in the upcoming year. However, the main drawback of the Z-score is it does not apply to banks and insurance companies. According to Investopedia, the concept of "working capital" does not apply to banks and insurance companies, as financial institutions do not have typical current assets or current liabilities like inventories or accounts payable.


Collegium Pharmaceutical Probability of Financial Distress (%) Related Terms


FRA:354 vs XERS, ALVO, PAHC: Probability of Financial Distress (%) Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Collegium Pharmaceutical's Probability of Financial Distress (%), along with its competitors' market caps and Probability of Financial Distress (%) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Collegium Pharmaceutical Probability of Financial Distress (%) vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Collegium Pharmaceutical's Probability of Financial Distress (%) distribution charts can be found below:

* The bar in red indicates where Collegium Pharmaceutical's Probability of Financial Distress (%) falls into.


FRA:354
76GF Score
Collegium Pharmaceutical Inc FRA:354
Probability of Financial Distress (%) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Collegium Pharmaceutical Probability of Financial Distress (%) Calculation

Probability of Financial Distress (%) (PFD) was developed by John Campbell, Jens Hilscher and Jan Szilagyi in their Search of Distress Risk. It measures the probability that a company will go bankrupt within the next 12 months given its current financial position.

The Probability of Financial Distress (%) was obtained by a logit probability model based on eight explanatory variables. The logit formula to compute the probability of financial distress (LPFD) is given below:

LPFD= -20.12 * NIMTAAVG + 1.60 * TLMTA - 7.88 * EXRETAVG + 1.55 * SIGMA - 0.005 * RSIZE - 2.27 * CASHMTA + 0.070 * MB - 0.09 * PRICE -8.87
=-7.70

The Probability of Financial Distress (%) (PFD) was then obtianed by:

PFD=1/(1 + e^(-LPFD))*100%
=0.05%

The eight explanatory variables are:

1. NIMTAAVG = Net Income to Market Total Assets

NIMTAAVG=Net Income / Market Total Assets
=Net Income / (Market Cap + Total Liabilities)

*Note that for companies reported quarterly, geometrically declining weighted quarterly Net Income data in latest four quarters are used.

2. TLMTA = Total liabilities to Market Total Assets

TLMTA=Total Liabilities / Market Total Assets

3. CASHMTA = Cash to Market Total Assets

For non-financial companies, CASHMTA is measured as:

CASHMTA=Cash, Cash Equivalents, Marketable Securities / Market Total Assets

4. EXRETAVG = Excess Return compared to the S&P 500

EXRETAVG is the weighted excess return compared to the S&P 500 in past 12 month. Geometrically declining weights are imposed on the monthly excess return to reflect lagged information. The weight is halved each quarter.

5. SIGMA = Standard Deviation of Daily Returns

For sigma, we use the annualized standard deviation of a company's returns over the past 92 days (or 63 trading days).

6. RSIZE = Relative Size

RSIZE=log (Market Cap / Total Market Cap of S&P 500 companies)

7. MB = Market to Adjusted Book Equity Ratio


8. PRICE

PRICE is measured as the log of the stock price, capped at log(15).

What does a Probability of Financial Distress (%) of 0.05% mean?
Collegium Pharmaceutical (FRA:354) has a Probability of Financial Distress (%) of 0.05% as of Jun. 24, 2026.
Is Collegium Pharmaceutical's Probability of Financial Distress (%) too high?
Collegium Pharmaceutical's current Probability of Financial Distress (%) is 0.05%. Overall, Collegium Pharmaceutical has a GF Score™ of 76/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Collegium Pharmaceutical's Probability of Financial Distress (%) compare to XERS and ALVO?
Collegium Pharmaceutical's Probability of Financial Distress (%) of 0.05% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Probability of Financial Distress (%) for a Drug Manufacturers company?
A good Probability of Financial Distress (%) depends on the Drug Manufacturers industry context. However, Probability of Financial Distress (%) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Probability of Financial Distress (%) mean?
A high Probability of Financial Distress (%) can signal that a stock is expensive relative to its fundamentals. Collegium Pharmaceutical's current Probability of Financial Distress (%) is 0.05%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Collegium Pharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, Collegium Pharmaceutical (FRA:354) is currently considered Modestly Undervalued. The stock's GF Value™ is €35.50, compared to a current price of €28.80 — trading 18.9% below its estimated fair value. The current Probability of Financial Distress (%) is 0.05%. Collegium Pharmaceutical's overall GF Score™ is 76/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Probability of Financial Distress (%) calculated?
Probability of Financial Distress (%) is calculated from a company's financial statements. For Collegium Pharmaceutical (FRA:354), the current Probability of Financial Distress (%) is 0.05% as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Collegium Pharmaceutical (FRA:354) Overvalued in 2026?

Based on GuruFocus' analysis, Collegium Pharmaceutical stock appears to be undervalued. The current stock price of €28.80 is trading 18.9% below its estimated GF Value™ of €35.50. GuruFocus considers Collegium Pharmaceutical to be Modestly Undervalued.

Key valuation signals for FRA:354:

  • Probability of Financial Distress (%): 0.05%
  • GF Value™: €35.50 vs. price of €28.80 (18.9% below fair value)
  • GF Score™: 76/100 with 3 warning signs

No single metric tells the full story. See the FRA:354 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Collegium Pharmaceutical Business Description

Other Exchanges COLL:USA354:Germany
Address 100 Technology Center Drive, Stoughton, MA, USA, 02072
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.
76GF Score

Get the complete analysis for FRA:354

Probability of Financial Distress (%) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€28.80
Price
€35.50
GF Value